• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Lunit wins CE Mark for AI-based breast cancer detection software

Lunit wins CE Mark for AI-based breast cancer detection software

June 2, 2020 By Sean Whooley

Lunit announced today that it received CE Mark approval in Europe for its Lunit Insight MMG artificial intelligence-based software.

Insight MMG uses AI to analyze mammography images and provide the location of lesions that are suspicious for breast cancer, along with an abnormality score that reflects the probability of the existence of detected lesions. According to a news release, the software analyzes the images with 97% accuracy.

Lunit touted a recently published study in which AI alone showed 88.8% sensitivity in breast cancer detection, while radiologists alone showed 75.3%. When radiologists were aided by AI, their accuracy increased to 84.8%. This data came from a set of over 36,000 biopsy-proven, independent cancer-positive cases.

“Among the patients suspicious of breast cancer upon screening mammography, only 29% is actually diagnosed with cancer after a biopsy,” Lunit CEO Brandon Suh said in the release. “I am delighted to introduce Lunit Insight MMG, now CE certified, to healthcare professionals and institutions across the continent of Europe.

“With our AI software, we would like to increase the effectiveness of mammography screening and reduce unnecessary biopsies.”

Last November, Seoul-based Lunit received CE Mark approval for its Insight CXR up-to-date chest X-ray analysis AI that is capable of detecting 10 major chest abnormalities, including nodule, calcification, pneumothorax, consolidation, fibrosis and more, while also supporting tuberculosis screening.

Filed Under: Health Technology, Imaging, Mammography, Oncology, Regulatory/Compliance, Software / IT Tagged With: CE Mark, Lunit

More recent news

  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt
  • Penumbra completes enrollment in pulmonary embolism trial

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy